BACKGROUND: The requirements for magnesium (Mg) supplementation increase under regional citrate anticoagulation (RCA) because citrate acts by chelation of bivalent cations within the blood circuit. The level of magnesium in commercially available fluids for continuous renal replacement therapy (CRRT) may not be sufficient to prevent hypomagnesemia. METHODS: Patients (n = 45) on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min) with RCA modality (4% trisodium citrate) using calcium free fluid with 0.75 mmol/l of Mg with additional magnesium substitution were observed after switch to the calcium-free fluid with magnesium concentration of 1.50 mmol/l (n = 42) and no extra magnesium replenishment. All patients had renal indications for CRRT, were treated with the same devices, filters and the same postfilter ionized calcium endpoint (<0.4 mmol/l) of prefilter citrate dosage. Under the high level Mg fluid the Qb, dosages of citrate and CRRT were consequently escalated in 9h steps to test various settings. RESULTS: Median balance of Mg was -0.91 (-1.18 to -0.53) mmol/h with Mg 0.75 mmol/l and 0.2 (0.06-0.35) mmol/h when fluid with Mg 1.50 mmol/l was used. It was close to zero (0.02 (-0.12-0.18) mmol/h) with higher blood flow and dosage of citrate, increased again to 0.15 (-0.11-0.25) mmol/h with 3,000 ml/h of high magnesium containing fluid (p<0.001). The arterial levels of Mg were mildly increased after the change for high level magnesium containing fluid (p<0.01). CONCLUSIONS: Compared to ordinary dialysis fluid the mildly hypermagnesemic fluid provided even balances and adequate levels within ordinary configurations of CRRT with RCA and without a need for extra magnesium replenishment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01361581.

Dept of Anesthesiology and Intensive Care 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Dept of Clinical Biochemistry 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

See more in PubMed

Fairley J GN, Zhang L, Bellomo R (2015) Magnesium status and magnesium therapy in critically ill patients: A systematic review J Crit Care 30: 1349–1358. 10.1016/j.jcrc.2015.07.029 PubMed DOI

Seabra VF BE, Liangos O, Sosa MA, Cendoroglo M, Jaber BL (2008) Timing of Renal Replacement Therapy Initiation in Acute Renal Failure: A Meta-analysis. Am J Kidney Dis 52. PubMed

Karvellas CJ FM, Sajjad I, Mogensen SS, Leung AA, Wald R, Bagshaw SM (2011) A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Critical Care 15. PubMed PMC

Escuela MP, Guerra M, Anon JM, Martinez-Vizcaino V, Zapatero MD, et al. (2005) Total and ionized serum magnesium in critically ill patients. Intensive Care Med 31: 151–156. PubMed

Huijgen HJ, Soesan M, Sanders R, Mairuhu WM, Kesecioglu J, et al. (2000) Magnesium levels in critically ill patients. What should we measure? Am J Clin Pathol 114: 688–695. PubMed

Hébert P MN, Wang J, Hindmarsh T, Jones G, Cardinal P (1997) Functional magnesium deficiency in critically ill patients identified using a magnesium-loading test. Crit Care Med 25: 749–755. PubMed

Brain M AM PS, Fowler P, (2012) Magnesium flux during continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 14: 274–282. PubMed

Tong GM RR (2005) Magnesium deficiency in critical illness. J Intensive Care Med 20: 3–17. PubMed

Zakharchenko M LP, Rulisek J, Los F, Brodska H, Balik M (2016) Ionized Magnesium and Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy. Blood Purif 41: 41–47. 10.1159/000440972 PubMed DOI

Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, et al. (2009) Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 37: 545–552. 10.1097/CCM.0b013e3181953c5e PubMed DOI

Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, et al. (2011) Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 26: 232–239. 10.1093/ndt/gfq575 PubMed DOI

Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, et al. (2012) Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 59: 810–818. 10.1053/j.ajkd.2011.11.030 PubMed DOI

Zhang Z, Hongying N (2012) Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 38: 20–28. 10.1007/s00134-011-2438-3 PubMed DOI

Global KDI, Group OKAKIW (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter 2: 1–138.

Dorval M, Madore F, Courteau S, Leblanc M (2003) A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration. Intensive Care Med 29: 1186–1189. PubMed

Morgera S HM, Ruckert M, Krieg H, Kastrup M, Krausch D, Vargas-Hein O, Zuckermann-Becker H, Peters H, Pohlmeier R, Neumayer HH (2005) Regional citrate anticoagulation in continuous hemodialysis—acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 101: c211–219. PubMed

Brain M, Parkes S, Fowler P, Robertson I, Brown A (2011) Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 13: 72–81. PubMed

Soliman HM, Mercan D, Lobo SS, Melot C, Vincent JL (2003) Development of ionized hypomagnesemia is associated with higher mortality rates. Crit Care Med 31: 1082–1087. PubMed

Matias PJ AA LI, Navarro D, Mendes M, Ferreira C, Amaral T, Jorge C, Aires I, Gil C, Ferreira A (2014) Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 38: 244–252. 10.1159/000366124 PubMed DOI

Cascaes Alves S DTC CL, Giombelli V, Candal R, de Lourdes Bristot M, Topanotti MF, Burdmann EA, Dal-Pizzol F, Mazon Fraga C and Ritter C (2013) Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28: 910–916. 10.1093/ndt/gfs268 PubMed DOI

Balik M Zakharchenko M, Leden P, et al. (2014) The Effects of a Novel Calcium-Free Lactate Buffered Dialysis and Substitution Fluid for Regional Citrate Anticoagulation—Prospective Feasibility Study. Blood Purif 38: 263–272 10.1159/000369956 PubMed DOI

Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361: 1627–1638. 10.1056/NEJMoa0902413 PubMed DOI

Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, et al. (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359: 7–20. 10.1056/NEJMoa0802639 PubMed DOI PMC

Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, et al. (2004) Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 97: c131–136. PubMed

Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, et al. (2009) A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 37: 2018–2024. 10.1097/CCM.0b013e3181a00a92 PubMed DOI

Relton S, Greenberg A, Palevsky PM (1992) Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 38: M691–696. PubMed

Balik M, Zakharchenko M, Otahal M, Hruby J, Polak F, et al. (2012) Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy. Blood Purif 33: 80–87. 10.1159/000334641 PubMed DOI

Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R (2003) Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 29: 575–578. PubMed

Balik M, Zakharchenko M, Leden P, Otahal M, Hruby J, et al. (2013) Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin. J Crit Care 28: 87–95. 10.1016/j.jcrc.2012.06.003 PubMed DOI

Balik M, Waldauf P, Plasil P, Pachl J (2005) Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 23: 325–329. PubMed

Cole L BR, Baldwin I, et al. (2003) The impact of lactate-buffered high-volume hemofiltration on acid-base balance. Intensive Care Med 29: 1113–1120. PubMed

Bollmann MD RJ, Tappy L, Berger MM, Schaller MD, Cayeux MC, Martinez A, Chiolero RL (2004) Effect of bicarbonate and lactate buffer on glucose and lactate metabolism during hemodiafiltration in patients with multiple organ failure. Intensive Care Med 30: 1103–1110. PubMed

See more in PubMed

ClinicalTrials.gov
NCT01361581